Skip to main content

AS/Spondyloarthritis

      Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.
      Video: The PsA SpA Paradox of Choice

      Dr. Rachel Tate ( @uptoTate) reviews Dr. Laura Coates' presentation Personalized T

      Dr. John Cush RheumNow

      4 years 1 month ago
      Video: The PsA SpA Paradox of Choice Dr. Rachel Tate ( @uptoTate) reviews Dr. Laura Coates' presentation Personalized Treatment Strategies in Psoriatic Arthritis, given at the virtual #EULAR2021 meeting. https://t.co/Yg12SHR1MF https://t.co/UiCYDU5XGc
      Video: Nr-axSpA vs axSpA — does it matter? Dr. Meral El Ramahi (@MeralElRamahiMD ) #EULAR2021

      https://t.co/ocyR4ka8z

      Dr. John Cush RheumNow

      4 years 1 month ago
      Video: Nr-axSpA vs axSpA — does it matter? Dr. Meral El Ramahi (@MeralElRamahiMD ) #EULAR2021 https://t.co/ocyR4ka8zO https://t.co/DxHjM0stKo
      Here are a few notable presentations from this past Friday, Day 3 of the EULAR 2021 virtual meeting.
      The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a broad scale, has provided much-needed reassuring answers.
      RT @MeralElRamahiMD: OP0140 at #EULAR2021:
      ➡️Obs, prospect Nordic study characterized axSpA pts w/ high BASDAI + ASD

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 1 month ago
      OP0140 at #EULAR2021: ➡️Obs, prospect Nordic study characterized axSpA pts w/ high BASDAI + ASDAS & multiple bDMARD use (indicating difficult to tx dz) ➡️1 in 10 received at least 3 bDMARDs *⃣Multiple switchers were more often F, had higher b/l dz activity, & psoriasis @Rheumnow https://t.co/syq0szVWKe
      RT @MeralElRamahiMD: ⭐️TORTUGA = PII trial that showed filgotinib (Jak1-i) signif improv SPARCC MRI scores (BM edema

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 1 month ago
      ⭐️TORTUGA = PII trial that showed filgotinib (Jak1-i) signif improv SPARCC MRI scores (BM edema) in the spine + SIJ vs PBO in pts w/ active AS ⭐️OP0141 = post-hoc analysis that showed stat signif ⬇️ of CANDEN MRI scores (new bone format) w/ filgot at wk12 #EULAR2021 @Rheumnow https://t.co/RIpYIMcx1Q
      RT @MeralElRamahiMD: ➡️Netakimab = IL17Ai approved for AS, PsA, & Pso in Russia & Belarus

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 1 month ago
      ➡️Netakimab = IL17Ai approved for AS, PsA, & Pso in Russia & Belarus
      RT @ejdein1: #EULAR2021 POS0236
      Comparison of work productivity b/w CBP w & w/o AxSpA - 2 years from SPACE cohort
      â

      Eric Dein ejdein1

      4 years 1 month ago
      #EULAR2021 POS0236 Comparison of work productivity b/w CBP w & w/o AxSpA - 2 years from SPACE cohort ⭐️AxSpA showed significant ⬇️ in work productivity loss (WPL) compared to CBP wo AxSpA Can use to counsel AxSpA patients that we have effective Rx for return to work @RheumNow
      RT @ejdein1: #EULAR2021 POS0237: Gut dysbiosis linked to worse disease status in axSpA.
      ⭐️Dysbiosis in 33% of AxSpA

      Eric Dein ejdein1

      4 years 1 month ago
      #EULAR2021 POS0237: Gut dysbiosis linked to worse disease status in axSpA. ⭐️Dysbiosis in 33% of AxSpA vs 17% of controls wo rheumatic disease ⭐️Gut dysbiosis associated with worsening disease activity @RheumNow https://t.co/rRl4Zbs7xc
      RT @drdavidliew: 6. Rheum disease activity was stable with COVID vaccination.

      (RA, PsA, axSpA, SLE - total n = 597)
      7/

      David Liew drdavidliew

      4 years 1 month ago
      6. Rheum disease activity was stable with COVID vaccination. (RA, PsA, axSpA, SLE - total n = 597) 7/ LB0003 #EULAR2021 @RheumNow https://t.co/xxkrunjPa0
      RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb,

      Dr. John Cush RheumNow

      4 years 1 month ago

      RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow & its faculty.

      ×